% | $
Quotes you view appear here for quick access.

Metabolix, Inc. Message Board

reddywilling 3 posts  |  Last Activity: Apr 12, 2016 7:09 PM Member since: Nov 25, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Topsalysin Abstract at AUA 2016

    by iome70 Apr 4, 2016 3:11 PM
    reddywilling reddywilling Apr 12, 2016 7:09 PM Flag

    Saturday, May 7, 2016 10:30 AM-11:30 AM
    Late-Breaking Science & Technology Poster
    Funding: Sophiris Bio Corp
    LB-S&T-04: Prospective, Randomized, Double Blind, Vehicle Controlled, Multinational, Phase 3 Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia
    Claus Roehrborn*, Dallas, TX, Reginald Bruskewitz, Madison, WI, Richard Yocum, Allison Hulme, La Jolla, CA, Marc Gittelman, Aventura, FL
    Abstract: LB-S&T-04
    Introduction and Objectives
    Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) desire treatment options besides medications, which have side effects and lack of sustainability, and more invasive surgical interventions, which also have side effects and complications. PRX302 (topsalysin) is a genetically modified pore-forming protein (aerolysin) activated intraprostatically only by enzymatically active PSA, and thus a specific, highly-targeted, localized approach to lysing cells in the prostate transition zone.

    479 patients from 75 sites in 6 countries with International Prostate Symptom Score (IPSS) =15, peak urine flow (Qmax) 5-15 mL/s, and prostate volume (PV) 30-100 mL were randomized 1:1 to a single transrectal intraprostatic injection of PRX302 vs. placebo (vehicle) and then monitored for 52 weeks. BPH medications were washed out and prohibited on study. Injection was 20% of PV and 0.6 ug PRX302/g PV.

    92% of patients completed all 52 weeks. A single administration of PRX302 provided 7.6 points mean improvement in LUTS that was statistically significantly superior to vehicle-only injection, sustained through the Week 52 end of monitoring. This IPSS primary endpoint efficacy was supported by secondary endpoints, including positive findings for Qmax and two patient-rated disease-specific quality of life instruments. Relative to vehicle, PRX302-apparent toxicity was in general mild, transient, limited to irritative urinary

  • Did not like the top action today. The strength of the sellers into the 1.47 - 1.53 runup was too strong given the overall volume. ARNA has made a similar move and NT all in all bought 1mm shares for 1.2mm dollars this could just have been a window dress average price to balance the portfolio - they had already owned 12.5 mm
    may be wrong - usually am :( but next week we will see how much I left on the table

  • Reply to

    Vvus today and next week

    by pmt4111 Apr 1, 2016 3:07 PM
    reddywilling reddywilling Apr 1, 2016 6:53 PM Flag

    This is starting to look like an equity raise or a change in the executive office. Too much selling at the top today.....

0.92+0.12(+15.00%)Jun 24 4:00 PMEDT